Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mometasone furoate monohydrate, quantity: 51.73 microgram/actuation (equivalent: mometasone furoate, qty 50 microgram/actuation) - spray, suspension - excipient ingredients: glycerol; polysorbate 80; sodium citrate dihydrate; benzalkonium chloride; citric acid monohydrate; microcrystalline cellulose; carmellose sodium - mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis in adults, adolescents and children between the ages of 3 and 11 years.,mometasone aqueous nasal spray 0.05% is also indicated for the treatment of nasal polyps in adult patients 18 years of age and older.,mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with acute rhinosinusitis in patients 12 years of age and older without signs or symptoms of severe bacterial infection.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mometasone furoate monohydrate, quantity: 51.73 microgram/actuation (equivalent: mometasone furoate, qty 50 microgram/actuation) - spray, suspension - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; benzalkonium chloride; glycerol; polysorbate 80; microcrystalline cellulose; carmellose sodium - mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis in adults, adolescents and children between the ages of 3 and 11 years.,mometasone aqueous nasal spray 0.05% is also indicated for the treatment of nasal polyps in adult patients 18 years of age and older.,mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with acute rhinosinusitis in patients 12 years of age and older without signs or symptoms of severe bacterial infection.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mometasone furoate monohydrate, quantity: 51.73 microgram/actuation (equivalent: mometasone furoate, qty 50 microgram/actuation) - spray, suspension - excipient ingredients: glycerol; sodium citrate dihydrate; benzalkonium chloride; citric acid monohydrate; polysorbate 80; microcrystalline cellulose; carmellose sodium - mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis in adults, adolescents and children between the ages of 3 and 11 years.,mometasone aqueous nasal spray 0.05% is also indicated for the treatment of nasal polyps in adult patients 18 years of age and older.,mometasone aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with acute rhinosinusitis in patients 12 years of age and older without signs or symptoms of severe bacterial infection.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 1 mg/g - lotion - excipient ingredients: isopropyl alcohol; phosphoric acid; hyprolose; propylene glycol; monobasic sodium phosphate dihydrate; purified water - indications: elocon lotion (mometasone furoate) is indicated for-: short-term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, such as psoriasis and atopic dermatitis. - the short-term use for scalp psoriasis and seborrhoeic dermatitis.

Malta - inglés - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - mometasone furoate - ointment - mometasone furoate 0.1 % (w/w) - corticosteroids, dermatological preparations

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

multichem nz limited - mometasone furoate 1.02 mg/g - topical cream - 0.1% w/w - active: mometasone furoate 1.02 mg/g excipient: cetomacrogol 1000 cetostearyl alcohol dimeticone disodium edetate dihydrate hexylene glycol imidurea light liquid paraffin methyl hydroxybenzoate propyl hydroxybenzoate purified water - for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

multichem nz limited - mometasone furoate 1 mg/g (manufacturing formula includes includes 2 % overage (1.02 mg/g)); mometasone furoate 1 mg/g (manufacturing formula includes includes 2 % overage (1.02 mg/g)) - topical ointment - 0.1% w/w - active: mometasone furoate 1 mg/g (manufacturing formula includes includes 2 % overage (1.02 mg/g)) excipient: hexylene glycol macrogol stearate 1500 polysorbate 80 white beeswax white soft paraffin active: mometasone furoate 1 mg/g (manufacturing formula includes includes 2 % overage (1.02 mg/g)) excipient: hexylene glycol macrogol stearate 1500 polysorbate 80 white beeswax white soft paraffin - for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - mometasone furoate monohydrate - nasal spray suspension - 50 mcg/acutuation - corticosteroids

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - mometasone furoate monohydrate - nasal spray suspension - 50 mcg/acutuation - corticosteroids

Malta - inglés - Medicines Authority

auden mckenzie (pharma division) limited - mometasone furoate 0.1 % (w/w) - cream